WO2021036200A1 - 微型智能海藻酸钙水凝胶末端操作器的制备方法 - Google Patents
微型智能海藻酸钙水凝胶末端操作器的制备方法 Download PDFInfo
- Publication number
- WO2021036200A1 WO2021036200A1 PCT/CN2020/073728 CN2020073728W WO2021036200A1 WO 2021036200 A1 WO2021036200 A1 WO 2021036200A1 CN 2020073728 W CN2020073728 W CN 2020073728W WO 2021036200 A1 WO2021036200 A1 WO 2021036200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogel
- calcium alginate
- alginate hydrogel
- self
- preparing
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 18
- 235000010410 calcium alginate Nutrition 0.000 title claims abstract description 17
- 239000000648 calcium alginate Substances 0.000 title claims abstract description 17
- 229960002681 calcium alginate Drugs 0.000 title claims abstract description 17
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 title claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 16
- 238000004070 electrodeposition Methods 0.000 claims abstract description 14
- 239000011521 glass Substances 0.000 claims abstract description 13
- 238000000151 deposition Methods 0.000 claims abstract description 8
- 230000008021 deposition Effects 0.000 claims abstract description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 6
- 238000004804 winding Methods 0.000 claims abstract description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 238000005096 rolling process Methods 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- -1 cells Substances 0.000 claims description 4
- 229920002120 photoresistant polymer Polymers 0.000 claims description 4
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract description 4
- 229940072056 alginate Drugs 0.000 abstract description 4
- 235000010443 alginic acid Nutrition 0.000 abstract description 4
- 229920000615 alginic acid Polymers 0.000 abstract description 4
- 239000002356 single layer Substances 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/44—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes for electrophoretic applications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D1/00—Electroforming
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D1/00—Electroforming
- C25D1/08—Perforated or foraminous objects, e.g. sieves
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D1/00—Electroforming
- C25D1/20—Separation of the formed objects from the electrodes with no destruction of said electrodes
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/007—Electroplating using magnetic fields, e.g. magnets
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/34—Pretreatment of metallic surfaces to be electroplated
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/60—Electroplating characterised by the structure or texture of the layers
- C25D5/605—Surface topography of the layers, e.g. rough, dendritic or nodular layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3515—Communication with implanted devices, e.g. external control using magnetic means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Definitions
- the present invention belongs to the technical field of pharmaceutical microcarriers, and specifically relates to a method for preparing a miniature smart calcium alginate hydrogel terminal manipulator based on different microelectrodes.
- Drug delivery refers to the delivery of drugs to a lesion site in a specific way, so as to achieve the purpose of treating diseases.
- Common clinical drug delivery methods include enteral administration, parenteral administration and local administration.
- Oral administration and rectal administration are two enteral administration methods. The drug is absorbed by the gastrointestinal mucosa, liver or rectal mucosa, and then enters the blood, and is transported to the whole body through the blood circulation to achieve the purpose of curing diseases.
- Intravenous injection, intramuscular injection, and subcutaneous injection are three common parenteral administration methods, which refer to the direct injection of drugs into veins, muscle tissues, and subcutaneous tissues.
- Local administration methods include drug delivery through the eyes, lungs, abdominal cavity, and skin, and direct delivery of the drug to the lesion site to achieve the purpose of curing the disease. Compared with systemic medication, local medication can achieve higher drug concentration and have fewer side effects. Has significant advantages. Although traditional drug delivery can have a certain effect on the diagnosis and treatment of certain specific diseases, most of them are faced with the problems of fast drug release, short drug action time, long-term and multiple administrations.
- microcarrier drug delivery system which has the characteristics of targeted controlled release, safety, reliability, and modification. According to clinical needs, selecting appropriate types of drug microcarriers can not only deliver drugs to the target organs at a specific point, but also effectively adjust the physical and chemical properties of the drugs, so as to achieve the effects of improving the treatment effect, reducing toxic side effects and reducing treatment costs.
- the purpose of the present invention is to propose a method for preparing a miniature smart calcium alginate hydrogel terminal manipulator based on different microelectrodes.
- the technical scheme of the present invention is as follows:
- the present invention proposes a method for manufacturing a micro-manipulator with different structures based on different micro-electrodes to realize different functions, including: electrodeposition , Processing, picking up.
- the electrodeposition further includes: a1: coating the FTO glass by a spin coater and forming different microelectrodes by photolithography; a2: Fill the deposition solution between the two electrodes, which are maintained by two insulating spacers with a height of 1 mm; a3: apply a DC voltage to the electrodes for a duration of 1-5 seconds; a4: buffer the anode in HEPES Wash in the solution for 5 minutes until all the hydrogel microstructures are separated from the ITO glass.
- the electrodeposition step further includes: a1: coating photoresist on the FTO glass by a spin coater, and forming a concave pattern of a specific shape on the FTO glass as an anode; a2: filling the deposition solution to two Between the electrodes, it is maintained by insulating gaskets; a3: apply a DC voltage to the electrodes for a duration of 1-5 seconds; a4: wash the anode in HEPES buffer.
- the number of insulating gaskets is not less than two, and the thickness of the respective insulating gaskets is not less than 1 mm.
- the washing time is 3-10 minutes.
- the processing further includes: b1: transferring the hydrogel microstructure to a calcium chloride solution for 2 minutes to make the hydrogel microstructure fully self-winding; preferably, the picking up further includes: c1: collect the microstructures in a petri dish; c2: store the petri dish in a specific environment.
- the deposition solution includes CdCO 3 , drugs, cells, magnetic nanoparticles and monitoring equipment.
- FIG. 1 is a schematic diagram of a micro-tissue construction device based on electrodeposition of the present invention
- FIG. 1a is a schematic diagram of strip-shaped hydrogel electrodeposition
- FIG. 1b is a schematic diagram of radial hydrogel electrodeposition
- Fig. 2 is a schematic diagram of the microstructure of an alginate monolayer film
- Fig. 2a and Fig. 2b are the striped and radial hydrogel microstructures after electrodeposition.
- Figure 3 is a schematic diagram of the self-rolling deformation of the microstructure of an alginate monolayer membrane
- Figure 3a and Figure 3b are schematic diagrams of the shape of the strip-shaped hydrogel microstructure after self-curling
- Figure 3c is the shape of the radial hydrogel microstructure after self-curling Schematic.
- the present invention provides a method for preparing a degradable and self-winding miniature intelligent calcium alginate hydrogel terminal manipulator, which includes electrodeposition, processing, and picking.
- the electrodeposition further includes:
- the S11 further includes:
- a photoresist with a thickness of about 10 M m is used to form a concave pattern of a specific shape on the FT0 glass as an anode;
- the processing further includes:
- the pickup further includes: si: collecting the microstructures in a petri dish;
- the required components include CaCO 3 , drugs, cells, magnetic nanoparticles, monitoring equipment, and the like.
- the above description is only a specific embodiment of the present invention, and the above embodiments are only used to illustrate the technical solutions and inventive concepts of the present invention and do not limit the scope of the claims of the present invention. Any other technical solutions that can be obtained by logical analysis, reasoning or limited experiments by those skilled in the art on the basis of the inventive concept of this patent in combination with the existing technology should also be considered to fall within the protection scope of the claims of the present invention. .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Metallurgy (AREA)
- Electrochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/142,264 US20210222310A1 (en) | 2019-08-26 | 2021-01-06 | Preparation method of miniature intelligent calcium alginate hydrogel end operator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910788938.7 | 2019-08-26 | ||
CN201910788938.7A CN110548214B (zh) | 2019-08-26 | 2019-08-26 | 微型智能海藻酸钙水凝胶末端操作器的制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/142,264 Continuation-In-Part US20210222310A1 (en) | 2019-08-26 | 2021-01-06 | Preparation method of miniature intelligent calcium alginate hydrogel end operator |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021036200A1 true WO2021036200A1 (zh) | 2021-03-04 |
Family
ID=68736649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/073728 WO2021036200A1 (zh) | 2019-08-26 | 2020-01-22 | 微型智能海藻酸钙水凝胶末端操作器的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210222310A1 (zh) |
CN (1) | CN110548214B (zh) |
WO (1) | WO2021036200A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110548214B (zh) * | 2019-08-26 | 2021-08-31 | 北京理工大学 | 微型智能海藻酸钙水凝胶末端操作器的制备方法 |
CN114432229A (zh) * | 2022-02-10 | 2022-05-06 | 北京理工大学 | 一种靶向投递的微t型机器人装置及应用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009045221A (ja) * | 2007-08-20 | 2009-03-05 | Osaka Prefecture Univ | 神経再生誘導体 |
CN108853709A (zh) * | 2018-04-27 | 2018-11-23 | 清华大学 | 柔性水凝胶微针贴片及其制备方法 |
CN109022411A (zh) * | 2018-08-09 | 2018-12-18 | 北京理工大学 | 基于电沉积和机器人操作的3d微组织构建方法 |
CN110038166A (zh) * | 2019-04-24 | 2019-07-23 | 温州医科大学 | 一种应用于神经修复的自卷曲膜剂及其制备方法 |
CN110548214A (zh) * | 2019-08-26 | 2019-12-10 | 北京理工大学 | 微型智能海藻酸钙水凝胶末端操作器的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101461945A (zh) * | 2009-01-13 | 2009-06-24 | 武汉理工大学 | 海藻酸磁性材料的制备方法 |
CN102921010B (zh) * | 2012-11-22 | 2015-01-21 | 上海师范大学 | 磁性介孔生物玻璃药物传递系统及其制备方法 |
CN103849593B (zh) * | 2012-12-06 | 2016-08-10 | 中国科学院大连化学物理研究所 | 一种磁分离式细胞三维共培养方法 |
CN105079863A (zh) * | 2015-08-12 | 2015-11-25 | 中国科学院兰州化学物理研究所 | 一种芦荟/海藻酸钠双层水凝胶敷料的制备方法 |
CN108392672A (zh) * | 2018-03-23 | 2018-08-14 | 曹朗翘 | 三七海藻凝胶敷料及其制备方法 |
CN109294002B (zh) * | 2018-09-15 | 2021-05-04 | 深圳先进技术研究院 | 一种可控双向三维形变水凝胶薄膜及其制备方法和柔性微电极阵列 |
-
2019
- 2019-08-26 CN CN201910788938.7A patent/CN110548214B/zh active Active
-
2020
- 2020-01-22 WO PCT/CN2020/073728 patent/WO2021036200A1/zh active Application Filing
-
2021
- 2021-01-06 US US17/142,264 patent/US20210222310A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009045221A (ja) * | 2007-08-20 | 2009-03-05 | Osaka Prefecture Univ | 神経再生誘導体 |
CN108853709A (zh) * | 2018-04-27 | 2018-11-23 | 清华大学 | 柔性水凝胶微针贴片及其制备方法 |
CN109022411A (zh) * | 2018-08-09 | 2018-12-18 | 北京理工大学 | 基于电沉积和机器人操作的3d微组织构建方法 |
CN110038166A (zh) * | 2019-04-24 | 2019-07-23 | 温州医科大学 | 一种应用于神经修复的自卷曲膜剂及其制备方法 |
CN110548214A (zh) * | 2019-08-26 | 2019-12-10 | 北京理工大学 | 微型智能海藻酸钙水凝胶末端操作器的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20210222310A1 (en) | 2021-07-22 |
CN110548214A (zh) | 2019-12-10 |
CN110548214B (zh) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Claw-inspired microneedle patches with liquid metal encapsulation for accelerating incisional wound healing | |
Yan et al. | Aligned nanofibers from polypyrrole/graphene as electrodes for regeneration of optic nerve via electrical stimulation | |
Tandon et al. | Electroactive biomaterials: Vehicles for controlled delivery of therapeutic agents for drug delivery and tissue regeneration | |
Alshammary et al. | Electrodeposited conductive polymers for controlled drug release: polypyrrole | |
Zhang et al. | Bioinspired pagoda-like microneedle patches with strong fixation and hemostasis capabilities | |
Wang et al. | Insulin-loaded silk fibroin microneedles as sustained release system | |
Lu et al. | Electrodeposited polypyrrole/carbon nanotubes composite films electrodes for neural interfaces | |
KR101254240B1 (ko) | 마이크로구조체 제조방법 | |
Xu et al. | Self‐powerbility in electrical stimulation drug delivery system | |
WO2021036200A1 (zh) | 微型智能海藻酸钙水凝胶末端操作器的制备方法 | |
CN111643447B (zh) | 一种载药微针、载药微针贴片、电调控药物释放微针系统及载药微针制备方法 | |
US20160141065A1 (en) | Porous substrate electrode body and method for producing same | |
TW201043278A (en) | Microneedle array using porous basal disc and method for producing thereof | |
Choi et al. | Adhesive bioelectronics for sutureless epicardial interfacing | |
WO2017200213A1 (ko) | 마이크로니들 제조방법 | |
CN106730309A (zh) | 一种硅微针基板及其制备方法 | |
WO2022105824A1 (zh) | 一种载活菌的微针的制备方法及应用 | |
Zhang et al. | Fabrication of conducting polymer microelectrodes and microstructures for bioelectronics | |
Li et al. | Bioinspired flexible electronics for seamless neural interfacing and chronic recording | |
Liang et al. | Strategies for interface issues and challenges of neural electrodes | |
Raj et al. | Conductive polymers and composites-based systems: An incipient stride in drug delivery and therapeutics realm | |
Song et al. | Recent advances in 1D nanomaterial‐based bioelectronics for healthcare applications | |
Wei et al. | Physical cue‐based strategies on peripheral nerve regeneration | |
CN100579599C (zh) | 微针阵列注射器的制备方法 | |
US20220104748A1 (en) | Biocompatible and electroconductive polymeric microneedle biosensor for minimally invasive biosensing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20857900 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20857900 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 29/03/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20857900 Country of ref document: EP Kind code of ref document: A1 |